Advancing skin longevity through research and clinical validation

What will the fresh investment enable in terms of research priorities, formulation development and clinical validation?
The investment allows us to deepen our research capabilities, particularly in photobiology: understanding how different wavelengths of light interact with skin, and translating that knowledge into better photoprotection and care for pigmentation and skin ageing.
We also want to strengthen the exchange of knowledge between CHOSEN and our partner clinics. Dermatologists bring observations from everyday practice, including unmet needs, treatment responses and the difficulties people have in sustaining a routine. Our research can investigate these questions and bring the findings back into clinical practice.
The funding gives us greater capacity to connect these observations with formulation development and clinical validation. The Centre of Excellence is an important next step in making that exchange more systematic.
How will the Centre of Excellence strengthen your R&D capabilities and support clinically validated formulations?
The Centre of Excellence is intended to bring dermatologists more deeply into the research and development process, beginning with the questions we choose to investigate.
A dermatologist’s contribution extends well beyond evaluating a finished product. It includes identifying a clinical need, helping define the formulation brief, selecting meaningful study outcomes and interpreting whether the benefit is useful in practice.
We see this as a continuing exchange. Observations from partner clinics can inform our research priorities, while findings from our studies can support better informed product use and clinical protocols. It also creates opportunities to learn across different settings and populations.
For CHOSEN, the aim is to build on our clinical foundation and develop more Indian authored research, with formulations shaped by the needs of the people who use them.
How is the Indian cosmeceutical industry evolving in skin ageing, pigmentation and preventive skincare?
The conversation is expanding from addressing an existing concern to understanding how skin changes over time and what we can do earlier. Prejuvenation is part of this shift: taking sensible preventive steps before changes become more established.
An exposome lens makes this approach more relevant. Sun exposure, climate, pollution, sleep, stress and other influences form the context in which a skincare routine has to work. For Indian skin, this also means giving pigmentation, barrier health and tolerability greater attention within the ageing conversation.
There is also a need for better options between everyday skincare and procedures. People may notice changes in firmness or facial contours and want to begin addressing them at home before they feel ready for a procedure. That is the space we are exploring with CHOSEN Sculpt. It gives people an earlier point of entry into care, with expectations driven from actual clinical studies.
How is skin longevity changing R&D in active ingredients, formulation technologies and efficacy assessment?
Skin longevity requires us to think about both the benefit and duration of exposure. If we are developing products that people may use for years, we need to ask how effectively they work now and how appropriate they are for sustained use.
That brings safety over the long term, including the potential for endocrine disruption, into the research conversation. Ingredient selection needs to consider concentration, absorption, patterns of exposure and the available toxicological evidence, alongside efficacy. Formulation technologies should help us achieve a meaningful benefit with an appropriate exposure and tolerability profile.
Our ambition is care that is effective today and remains safe throughout its intended use. That requires continuing assessment as evidence develops.
Skinspan (the years skin remains healthy and functions well) only matters when lifespan (the total length of a person’s life) is factored into the thinking. It makes little sense for skin to look younger if the health of the rest of the body is being compromised. Maintaining the appearance and function of skin has to support the health of the whole person. That is the essence of the youthful and holistic longevity we pursue at CHOSEN.
Which advanced actives have the potential to make a meaningful difference?
Our work spans signalling peptides, plant extracts such as Pycnogenol®, DMAE and advances in photoprotection, including bemotrizinol. What interests me is how we can translate these ingredients into formulations that meet a specific clinical need.
We introduced Pycnogenol® into India and have built the widest range of oral and topical formulations containing it, including several first and only offerings. This reflects our interest in taking well characterised molecules through thoughtful formulation development, to serve outcomes relevant to the Indian exposome.
Innovation also comes from understanding where an established ingredient needs a different formulation. Even a familiar active such as tranexamic acid requires a distinct approach when we are developing a serum for pigmentation in sensitive skin damaged by steroid and skin lightening cream use. The formulation has to account for the compromised barrier, tolerability and the other ingredients that skin can comfortably accommodate. That is a different brief from using the same tranexamic acid in a multipurpose pigmentation serum.
As a doctor, you begin with the person in front of you. Their needs guide the choice of ingredient, the formulation and how you assess its benefit. Everything we develop has to serve that person. The same thinking guides our work with signalling peptides, DMAE and sunscreen filters.
What are the challenges in validating cosmeceuticals, and how can the industry strengthen evidence and safety?
Clinical studies are one of CHOSEN’s strengths, and an area in which we intend to keep investing as a point of differentiation.
Consumer research tells us whether a product is acceptable: whether people like its texture, find it comfortable and are willing to continue using it. Those findings matter because even a well designed formulation needs to fit into daily life. Clinical studies answer a further question: does the product deliver a meaningful, measurable benefit?
That requires relevant endpoints, appropriate study parameters and a duration suited to the claim. A pigmentation claim needs pigmentation assessment; a firmness claim needs measures that can substantiate changes in firmness. Satisfaction alone cannot establish either.
The industry can strengthen confidence by making the relationship between the study and the claim clearer, while assessing safety and tolerability with equal care. For us, clinical validation is part of product development, informing what we make, how we improve it and what we can responsibly say about it.
The post Advancing skin longevity through research and clinical validation appeared first on Express Pharma.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
